

# Contents

## Part I Design Considerations

<b>1 The Need for and the Future of Adaptive Designs in Clinical Development.....</b>	<b>3</b>
Christy Chuang-Stein and Frank Bretz	
<b>2 Regulatory Guidance Documents on Adaptive Designs: An Industry Perspective .....</b>	<b>25</b>
José Pinheiro	
<b>3 A Commentary on the U.S. FDA Adaptive Design Draft Guidance and EMA Reflection Paper from a Regulatory Perspective and Regulatory Experiences .....</b>	<b>43</b>
Sue-Jane Wang	
<b>4 Considerations and Optimization of Adaptive Trial Design in Clinical Development Programs.....</b>	<b>69</b>
Michael Krams and Vladimir Dragalin	
<b>5 Optimal Cost-Effective Go–No Go Decisions in Clinical Development.....</b>	<b>91</b>
Cong Chen, Robert A. Beckman, and Linda Z. Sun	
<b>6 Timing and Frequency of Interim Analyses in Confirmatory Trials.....</b>	<b>115</b>
Keaven M. Anderson	
<b>7 Approaches for Optimal Dose Selection for Adaptive Design Trials.....</b>	<b>125</b>
David Lawrence and Frank Bretz	
<b>8 A Review of Available Software and Capabilities for Adaptive Designs.....</b>	<b>139</b>
Yevgen Tymofyeyev	

<b>9</b>	<b>Randomization Challenges in Adaptive Design Studies.....</b>	<b>157</b>
	Olga M. Kuznetsova	
<b>10</b>	<b>Response-Adaptive Randomization for Clinical Trials .....</b>	<b>183</b>
	Lanju Zhang and William F. Rosenberger	
<b>Part II Trial Implementation Considerations</b>		
<b>11</b>	<b>Implementing Adaptive Designs: Operational Considerations, Putting It All Together.....</b>	<b>203</b>
	Olga Marchenko and Christy Nolan	
<b>12</b>	<b>Implementation Issues in Adaptive Design Trials.....</b>	<b>225</b>
	Linda Danielson, Jerome Carlier, Tomasz Burzykowski, and Marc Buyse	
<b>13</b>	<b>Implementing Adaptive Designs: Using Technology to Protect Trial Integrity, Reduce Operational Bias, and Build Regulatory Trust .....</b>	<b>241</b>
	Judith Quinlan and Michael Krams	
<b>14</b>	<b>Considerations for Interim Analyses in Adaptive Trials, and Perspectives on the Use of DMCs.....</b>	<b>259</b>
	Paul Gallo, David DeMets, and Lisa LaVange	
<b>15</b>	<b>Approaches for Clinical Supply Modelling and Simulation .....</b>	<b>273</b>
	Nitin R. Patel, Suresh Ankolekar, and Pralay Senchaudhuri	
<b>16</b>	<b>Approaches for Patient Recruitment Modeling and Simulation .....</b>	<b>299</b>
	Weili He and Xiting Cao	
<b>Part III Case Studies</b>		
<b>17</b>	<b>A Case Study for Adaptive Trial Design Consideration and Implementation.....</b>	<b>321</b>
	Vladimir Dragalin and Michael Krams	
<b>18</b>	<b>Case Study: Design Considerations for a Phase Ib Randomized, Placebo-Controlled, 4-Period Crossover Adaptive Dose-Finding Clinical Trial .....</b>	<b>341</b>
	James A. Bolognese and Yevgen Tymofyeyev	
<b>19</b>	<b>Continual Reassessment Method for a First-in-Human Trial: From Design to Trial Implementation .....</b>	<b>357</b>
	Inna Perevozskaya, Lixin Han, and Kristen Pierce	

**20 Practical Considerations for a Two-Stage Confirmatory Adaptive Clinical Trial Design and Its Implementation: ADVENT Trial ..... 383**  
Pravin R. Chaturvedi, Zoran Antonijevic, and Cyrus Mehta

**Index..... 413**

Practical Considerations for Adaptive Trial Design and  
Implementation

He, W.; Pinheiro, J.; Kuznetsova, O.M. (Eds.)

2014, XX, 416 p. 66 illus., 41 illus. in color., Hardcover

ISBN: 978-1-4939-1099-1